Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells - PubMed
- ️Thu Jan 01 2004
Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells
Noriyuki Ouchi et al. J Biol Chem. 2004.
Abstract
Adiponectin is an adipocyte-specific adipocytokine with anti-atherogenic and anti-diabetic properties. Here, we investigated whether adiponectin regulates angiogenic processes in vitro and in vivo. Adiponectin stimulated the differentiation of human umbilical vein endothelium cells (HUVECs) into capillary-like structures in vitro and functioned as a chemoattractant in migration assays. Adiponectin promoted the phosphorylation of AMP-activated protein kinase (AMPK), protein kinase Akt/protein kinase B, and endothelial nitric oxide synthesis (eNOS) in HUVECs. Transduction with either dominant-negative AMPK or dominant-negative Akt abolished adiponectin-induced eNOS phosphorylation as well as adiponectin-stimulated HUVEC migration and differentiation. Dominant-negative AMPK also inhibited adiponectin-induced Akt phosphorylation, suggesting that AMPK is upstream of Akt. Dominant-negative Akt or the phosphatidylinositol 3-kinase inhibitor LY294002 blocked adiponectin-stimulated Akt and eNOS phosphorylation, migration, and differentiation without altering AMPK phosphorylation. Finally, adiponectin stimulated blood vessel growth in vivo in mouse Matrigel plug implantation and rabbit corneal models of angiogenesis. These data indicate that adiponectin can function to stimulate the new blood vessel growth by promoting cross-talk between AMP-activated protein kinase and Akt signaling within endothelial cells.
Figures

Tube formation assays were performed (A and B). HUVECs were seeded on Matrigel-coated culture dishes in the presence of adiponectin (30 µg/ml), VEGF (20 ng/ml), or BSA (30 µg/ml) (Control). A, representative cultures are shown. B, quantitative analysis of tube formation. C, a modified Boyden chamber assay was performed using HUVECs. HUVECs were treated with adiponectin (30 µg/ml), VEGF (20 ng/ml), or BSA (30 µg/ml) (Control). Results are shown as mean ± S.E. Results are expressed relative to control. *, p < 0.01 versus control.

A, time-dependent changes in the phosphorylation (p-) of AMPK, Akt, eNOS, and extracellular signal-regulated kinase (ERK) after adiponectin treatment (30 µg/ml). B, role of AMPK in the regulation of adiponectin-induced protein phosphorylation. HUVECs were transduced with an adenoviral vector expressing dominant-negative AMPK tagged with c-Myc (dn-AMPK) or an adenoviral vector expressing green fluorescence protein (Control) 24 h before serum-starvation. After 16-h serum starvation, cells were treated with adiponectin (30 µg/ml) for the indicated lengths of time. C, role of Akt in the regulation of adiponectin-induced protein phosphorylation. HUVECs were transduced with an adenoviral vector expressing dominant-negative Akt (dn-Akt) or an adenoviral vector expressing green fluorescence protein (Control) 24 h before serum starvation. After 16 h of serum starvation, cells were treated with adiponectin (30 µg/ml) for the indicated lengths of time. Representative blots are shown.

HUVECs were transduced with an adenoviral vector expressing dn-AMPK (gray), dn-Akt (open) or green fluorescence protein (Control, solid) 24 h before the change to low-serum media. After 16 h of serum starvation, in vitro Matrigel (A and B) or modified Boyden chamber assays (C) were performed. Cells were treated with adiponectin (30 µg/ml) or BSA (30 µg/ml) (Vehicle). A, representative cultures displaying tube formation are shown. B, quantitative analysis of tube lengths. C, modified Boyden chamber assay was performed with adiponectin or VEGF as chemoattractant. Results are shown as the mean ± S.E. Results are expressed relative to control. *, p < 0.01 versus each control.

A, quantitative analysis of tube formation is shown. HUVECs were treated with adiponectin (30 µg/ml) or BSA (30 µg/ml) in the presence of LY294002 (10 µ
m) or vehicle at the time of seeding. B, a modified Boyden chamber assay was performed using adiponectin as the chemoattractant. HUVECs were pretreated with LY294002 (10 µ
m) or vehicle for 1 h and then incubated with adiponectin (30 µg/ml) or BSA (30 µg/ml) for 4 h. C, effects of LY294002 on adiponectin-stimulated protein phosphorylation (p-). Representative blots are shown. HUVECs were pretreated with LY294002 (10 µ
m) or vehicle for 1 h and then incubated with adiponectin (30 µg/ml) or BSA (30 µg/ml) for the indicated lengths of time. Results are presented as the mean ± S.E. For A and B, results are expressed relative to control. *, p < 0.01.

An in vivo Matrigel plug assay was performed to evaluate the effect of adiponectin on angiogenesis (A and B). Matrigel plugs containing adiponectin (100 µg/ml, n = 3) or phosphate-buffered saline (Control, n = 3) were injected subcutaneously into mice. A, plugs were stained with the endothelial cell marker CD31. Bar, 100 µm. B, the frequency of CD31-positive cells in five low power fields was determined for each Matrigel plug. Data were presented as fold increase of CD31-positive cells relative to the control. A rabbit cornea assay was performed (C and D). Pellets containing adiponectin (1 and 10 µg, n = 8), VEGF (100 ng, n = 8), or phosphate-buffered saline (Control, n = 8) were implanted in the cornea. C, photographs of rabbit eyes are shown (Control, adiponectin 10 µg; VEGF, 100 ng). D, an angiogenic score was calculated (vessel density × distance from limbus). Results are shown as the mean ± S.E. *, p < 0.01 versus control.

Adiponectin activates AMPK, which in turn promotes Akt activation, eNOS phosphorylation, and angiogenesis. PI3-kinase is essential for adiponectin-mediated activation of Akt. Both AMPK and Akt can directly phosphorylate eNOS. However, inhibition of Akt or PI3-kinase was found to suppress adiponectin-stimulated eNOS phosphorylation without interfering with AMPK activation. Therefore, the data are most consistent with an AMPK-PI3-kinase-Akt-eNOS-signaling axis.
Similar articles
-
Adiponectin stimulates production of nitric oxide in vascular endothelial cells.
Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Chen H, et al. J Biol Chem. 2003 Nov 7;278(45):45021-6. doi: 10.1074/jbc.M307878200. Epub 2003 Aug 27. J Biol Chem. 2003. PMID: 12944390
-
Zou MH, Hou XY, Shi CM, Nagata D, Walsh K, Cohen RA. Zou MH, et al. J Biol Chem. 2002 Sep 6;277(36):32552-7. doi: 10.1074/jbc.M204512200. Epub 2002 Jul 9. J Biol Chem. 2002. PMID: 12107173
-
Nagata D, Mogi M, Walsh K. Nagata D, et al. J Biol Chem. 2003 Aug 15;278(33):31000-6. doi: 10.1074/jbc.M300643200. Epub 2003 Jun 4. J Biol Chem. 2003. PMID: 12788940
-
Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, Bender JR. Haynes MP, et al. Circ Res. 2000 Oct 13;87(8):677-82. doi: 10.1161/01.res.87.8.677. Circ Res. 2000. PMID: 11029403
-
Nitric oxide and angiogenesis.
Ziche M, Morbidelli L. Ziche M, et al. J Neurooncol. 2000 Oct-Nov;50(1-2):139-48. doi: 10.1023/a:1006431309841. J Neurooncol. 2000. PMID: 11245273 Review.
Cited by
-
The Effect of Metabolites on Mitochondrial Functions in the Pathogenesis of Skeletal Muscle Aging.
Gu X, Wang W, Yang Y, Lei Y, Liu D, Wang X, Wu T. Gu X, et al. Clin Interv Aging. 2022 Aug 22;17:1275-1295. doi: 10.2147/CIA.S376668. eCollection 2022. Clin Interv Aging. 2022. PMID: 36033236 Free PMC article. Review.
-
Adiponectin potentiates the acute effects of leptin in arcuate Pomc neurons.
Sun J, Gao Y, Yao T, Huang Y, He Z, Kong X, Yu KJ, Wang RT, Guo H, Yan J, Chang Y, Chen H, Scherer PE, Liu T, Williams KW. Sun J, et al. Mol Metab. 2016 Aug 18;5(10):882-891. doi: 10.1016/j.molmet.2016.08.007. eCollection 2016 Oct. Mol Metab. 2016. PMID: 27689001 Free PMC article.
-
Regulation of Obesity by Antiangiogenic Herbal Medicines.
Shin SS, Yoon M. Shin SS, et al. Molecules. 2020 Oct 4;25(19):4549. doi: 10.3390/molecules25194549. Molecules. 2020. PMID: 33020443 Free PMC article. Review.
-
Cao J, Vecoli C, Neglia D, Tavazzi B, Lazzarino G, Novelli M, Masiello P, Wang YT, Puri N, Paolocci N, L'abbate A, Abraham NG. Cao J, et al. Front Physiol. 2012 Jun 4;3:160. doi: 10.3389/fphys.2012.00160. eCollection 2012. Front Physiol. 2012. PMID: 22675305 Free PMC article.
-
Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects.
Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM. Smith CC, et al. Br J Pharmacol. 2006 Sep;149(1):5-13. doi: 10.1038/sj.bjp.0706834. Epub 2006 Jul 17. Br J Pharmacol. 2006. PMID: 16847434 Free PMC article.
References
-
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Nature. 1994;372:425–432. - PubMed
-
- Hotamisligil GS, Shargill NS, Spiegelman BM. Science. 1993;259:87–91. - PubMed
-
- Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Nat. Med. 1996;2:800–803. - PubMed
-
- Trayhurn P, Beattie JH. Proc. Nutr. Soc. 2001;60:329–339. - PubMed
-
- Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. Biochem. Biophys. Res. Commun. 1996;221:286–289. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources